Trial Profile

ASP1585 Phase 3 Randomized Double Blind Placebo-controlled Study in Chronic Kidney Disease (CKD) Patients With Hyperphosphatemia Not on Dialysis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 19 Mar 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bixalomer (Primary)
Indications Hyperphosphataemia
Focus Therapeutic Use
Sponsors Astellas Pharma

Most Recent Events

17 Mar 2015 According to media release, Astellas Pharma has submitted a supplemental New Drug Application (sNDA) to the Ministry of Health, Labour and Welfare in Japan, for bixalomer [Kiklin] for treatment of hyperphosphatemia in patients with chronic kidney disease who are not on dialysis. Data from this and another phase III trial (CTP 700245026) were used in the sNDA application.
15 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
26 May 2014 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com